Litigation Details for Onyx Therapeutics, Inc. v. Qilu Pharma, Inc. (D. Del. 2017)
✉ Email this page to a colleague
Onyx Therapeutics, Inc. v. Qilu Pharma, Inc. (D. Del. 2017)
| Docket | ⤷ Sign Up | Date Filed | 2017-08-30 |
| Court | District Court, D. Delaware | Date Terminated | 2018-02-07 |
| Cause | 35:271 Patent Infringement | Assigned To | Leonard Philip Stark |
| Jury Demand | None | Referred To | |
| Patents | 7,232,818; 7,417,042; 7,491,704; 7,737,112; 8,129,346; 8,207,125; 8,207,126; 8,207,127; 8,207,297 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Onyx Therapeutics, Inc. v. Qilu Pharma, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Onyx Therapeutics, Inc. v. Qilu Pharma, Inc. (D. Del. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2018-02-01 | 12 | of U.S. Patent Nos. 7,737,112 (“the ’112 patent); 7,417,042 (“the ’042 patent”); 7,232,818 (“the ’818…112 patent, the ’042 patent, the ’818 patent, the ’704 patent, the ’346 patent, the ’125 patent, the …818 patent); 7,491,704 (“the ’704 patent”); 8,129,346 (“the ’346 patent”); 8,207,125 (“the ’125 patent…8,207,126 (“the ’126 patent”); 8,207,127 (“the ’127 patent”); and 8,207,297 (“the ’297 patent”) are invalid,…the ’126 patent, the ’127, and the ’297 patent (collectively, “the Patents-in-Suit”); and NOW, THEREFORE | External link to document | |
| 2017-08-30 | 4 | Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,417,042 B2; 7,232,818 B2; 7,491,704…2017 7 February 2018 1:17-cv-01235 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
